Looking for broad exposure to the Mid Cap Growth segment of the US equity market? You should consider the Invesco S&P MidCap Momentum ETF (XMMO) , a passively managed exchange traded fund launched on March 3, 2005.The fund is sponsored by Invesco. It has amassed assets over $4.16 billion, making it one of the larger ETFs attempting to match the Mid Cap Growth segment of the US equity market.Why Mid Cap GrowthMid cap companies have market capitalization between $2 billion and $10 billion. They usually have h ...

Launched on 10/21/2015, the SPDR Portfolio S&P 500 High Dividend ETF (SPYD) is a smart beta exchange traded fund offering broad exposure to the Style Box - Large Cap Value category of the market.What Are Smart Beta ETFs?Market cap weighted indexes were created to reflect the market, or a specific segment of the market, and the ETF industry has traditionally been dominated by products based on this strategy.A good option for investors who believe in market efficiency, market cap weighted indexes offer a low- ...

Designed to provide broad exposure to the Industrials - Aerospace & Defense segment of the equity market, the SPDR S&P Aerospace & Defense ETF (XAR) is a passively managed exchange traded fund launched on September 28, 2011.While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency.Sector ETFs are also funds of convenience, offering many ways to gain low risk an ...

Looking for broad exposure to the Consumer Discretionary - Retail segment of the equity market? You should consider the VanEck Retail ETF (RTH) , a passively managed exchange traded fund launched on December 20, 2011.An increasingly popular option among retail and institutional investors, passively managed ETFs offer low costs, transparency, flexibility, and tax efficiency; they are also excellent vehicles for long term investors.Sector ETFs are also funds of convenience, offering many ways to gain low risk ...

First Phosphate Graduates to Trading on OTCQX Best Market in the United StatesAugust 12, 2025 7:07 AM EDT | Source: First Phosphate Corp.Saguenay, Quebec--(Newsfile Corp. - August 12, 2025) -  First Phosphate Corp. (CSE: PHOS) (OTCQX: FRSPF) (FSE: KD0) ("First Phosphate" or the "Company") announces that, as of today, its common shares have graduated to trading on the OTCQX Best Market ("OTCQX") under the ticker symbol of FRSFP.Trading on OTCQX is expected to enhance the visibility and accessib ...

CrowdStrike TodayCRWDCrowdStrike$426.43 +1.94 (+0.46%) 52-Week Range$235.60▼$517.98Price Target$461.17Add to WatchlistCrowdStrike Holdings Inc. NASDAQ: CRWD is down 9.76% in the last 30 trading days. However, CRWD stock is still up 79% in 2025, making it one of the best-performing technology stocks in the S&P 500. The stock’s year-long rally started after the much-publicized outage caused by a faulty software update. The company took aggressive steps in damage control that restored customer confidence in t ...

FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST if Approved Public Offering Raised Total Gross Proceeds of up to $170 Million if all Warrants are Exercised $75 Million Royalty Purchase Agreement Payment from RTW Extended Through End of 2025 MONTREAL and CHARLOTTE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today re ...

- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Completed enrollment of Phase 2 MoonStone trial in Relapsing Multiple Sclerosis; results expected early in the fourth quarter 2025 - - Enrollment of Phase 2 SunStone trial in Systemic Lupus Erythematosus expected to be completed by year-end 2025; topline results expected mid-2026 - - Cash, cash equivalents and investments of $274.9 million as of June 30, 2025, expected to provide cash r ...

Core Insights - Cardinal Health reported fourth quarter fiscal year 2025 revenues of $60.2 billion, which is relatively flat compared to the same period in fiscal year 2024. Excluding the impact of a customer contract expiration, revenue increased by 21% [1][12] - The company achieved GAAP operating earnings of $428 million and GAAP diluted earnings per share (EPS) of $1.00 for the fourth quarter. Non-GAAP operating earnings rose by 19% to $719 million, with non-GAAP diluted EPS increasing by 13% to $2.08 [1][12] - For the full fiscal year 2025, revenues totaled $222.6 billion, a 2% decrease from fiscal year 2024. However, revenue increased by 18% when excluding the impact of the customer contract expiration [2][12] - Cardinal Health's CEO highlighted the operational strength across all five operating segments, which experienced double-digit profit growth, indicating effective execution of the company's growth strategy [3][12] Financial Performance - Fourth quarter fiscal year 2025 summary: - Revenue: $60.2 billion (Q4 FY24: $59.9 billion) - GAAP operating earnings: $428 million (Q4 FY24: $401 million, 7% increase) - Non-GAAP operating earnings: $719 million (Q4 FY24: $605 million, 19% increase) - Non-GAAP diluted EPS: $2.08 (Q4 FY24: $1.84, 13% increase) [4][12] - Full year fiscal year 2025 summary: - Revenue: $222.6 billion (FY24: $226.8 billion, 2% decrease) - GAAP operating earnings: $2.3 billion (FY24: $1.2 billion, 83% increase) - Non-GAAP operating earnings: $2.8 billion (FY24: $2.4 billion, 15% increase) - Non-GAAP diluted EPS: $8.24 (FY24: $7.53, 9% increase) [2][4] Segment Performance - Pharmaceutical and Specialty Solutions segment: - Q4 FY25 revenue: $55.4 billion (Q4 FY24: $55.6 billion) - Segment profit increased by 11% to $535 million in Q4 FY25 [5][6] - Global Medical Products and Distribution segment: - Q4 FY25 revenue: $3.2 billion (Q4 FY24: $3.1 billion, 3% increase) - Segment profit increased by 49% to $70 million in Q4 FY25 [7][8] - Other segment: - Q4 FY25 revenue: $1.6 billion (Q4 FY24: $1.2 billion, 37% increase) - Segment profit increased by 44% to $160 million in Q4 FY25 [9][10] Future Outlook - Cardinal Health raised its fiscal year 2026 outlook for non-GAAP diluted EPS to a range of $9.30 to $9.50, reflecting a growth of 13% to 15% [10][12] - The company anticipates revenue growth of 11% to 13% in the Pharmaceutical and Specialty Solutions segment and 2% to 4% in the Global Medical Products and Distribution segment for fiscal year 2026 [11][12]

Group 1 - The article questions whether Mistras Group is as financially troubled as it appears, suggesting that there may be underlying strengths not immediately visible [1] - The market's perception of Mistras Group has been influenced by recent performance, indicating a potential mispricing of the company's stock [1] Group 2 - The analysis implies that there could be investment opportunities in Mistras Group if the company's fundamentals are stronger than current market sentiment suggests [1]